Create Free Account

By creating account you will get access to hot stocks & personalised emails

Avita Therapeutics Inc

Healthcare AU AVH

2.78AUD
0.23(9.02%)

Last update at 2024-05-14T06:11:00Z

Day Range

2.552.83
LowHigh

52 Week Range

2.586.27
LowHigh

Financials

Income Statement

Balancesheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Type yearly yearly yearly yearly yearly
Date 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Income before tax -26.62900M -34.54513M -26.54500M -42.02600M -24.75004M
Minority interest - - - - -
Net income -26.66500M -34.60293M -26.58300M -42.03000M -24.62408M
Selling general administrative 23.33M 28.83M 22.40M 34.62M 12.67M
Selling and marketing expenses 21.91M 22.39M 14.66M 14.81M 12.31M
Gross profit 28.38M 37.05M 23.28M 11.29M 4.21M
Reconciled depreciation 0.57M - 0.71M 0.47M 0.26M
Ebit -27.50500M -34.51210M -27.23800M -41.99300M -24.98832M
Ebitda -26.04500M -33.58585M -26.52300M -41.52800M -24.72359M
Depreciation and amortization 1.46M 0.93M 0.71M 0.47M 0.26M
Non operating income net other - - - - -
Operating income -27.50500M -34.51210M -26.54000M -42.67900M -24.72359M
Other operating expenses 61.93M 63.16M 55.77M 56.94M 30.44M
Interest expense 0.02M 0.04M 0.02M 0.03M 0.03M
Tax provision 0.04M 0.03M 0.04M 0.00400M -0.17986M
Interest income 0.02M 0.02M 0.02M 0.03M -
Net interest income -0.01600M - -0.02200M -0.03300M -0.03777M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense 0.04M 0.06M 0.04M 0.00400M -0.12597M
Total revenue 34.42M 45.45M 29.23M 14.26M 5.40M
Total operating expenses 55.88M 71.56M 49.82M 53.97M 29.25M
Cost of revenue 6.04M 8.40M 5.95M 2.97M 1.19M
Total other income expense net 0.88M -0.03303M 0.02M 0.69M 0.32M
Discontinued operations - - - 1.54M -8.56421M
Net income from continuing ops -26.66500M - -26.58300M -42.03000M -35.16023M
Net income applicable to common shares -26.66500M -28.85400M -26.58300M -42.03000M -25.10200M
Preferred stock and other adjustments - - - - -
Breakdown 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Type yearly yearly yearly yearly yearly
Date 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Total assets 98.26M 159.67M 125.50M 82.46M 25.73M
Intangible assets 0.47M 0.61M 0.47M 0.36M 0.22M
Earning assets - - - - -
Other current assets 1.03M 0.20M 1.33M 0.99M 1.09M
Total liab 13.52M 12.59M 9.85M 10.06M 4.87M
Total stockholder equity 84.74M -324.69670M 115.66M 72.40M 20.86M
Deferred long term liab - 0.50M 0.61M - -
Other current liab 6.88M 8.86M 4.27M 3.38M 0.46M
Common stock 0.00300M 0.00413M 0.00300M 0.00300M 143.06M
Capital stock 0.00300M - 0.00300M 0.00300M 143.06M
Retained earnings -262.58800M -324.70082M -221.49600M -194.91300M -128.68946M
Other liab 2.52M 1.33M 1.58M 0.43M 0.47M
Good will - - - - -
Other assets 1.36M 1.30M 0.76M 0.00100M 0.00000M
Cash 18.16M 76.40M 110.75M 73.64M 20.30M
Cash and equivalents - 55.51M 110.75M - -
Total current liabilities 10.69M 12.59M 7.39M 7.71M 4.40M
Current deferred revenue 0.19M - - - -
Net debt -17.24600M -76.39979M -109.86800M -71.72200M -20.26041M
Short term debt 0.61M 0.00000M 0.00000M 0.00000M 4.39M
Short long term debt - - - - 4.39M
Short long term debt total 0.92M - 0.88M 1.92M 0.04M
Other stockholder equity 339.70M 324.70M 328.89M 259.17M 8.18M
Property plant equipment 2.05M 2.81M 2.94M 3.71M 1.31M
Total current assets 87.46M 126.80M 121.33M 78.39M 24.22M
Long term investments 6.93M - - - 0.01M
Net tangible assets 84.28M 104.18M 115.18M 72.04M 20.61M
Short term investments 61.18M 40.81M - - 0.28M
Net receivables 4.96M 3.51M 7.40M 2.43M 2.09M
Long term debt - - - - -
Inventory 2.12M 2.93M 1.65M 1.12M 0.74M
Accounts payable 3.00M 3.73M 3.12M 4.33M 3.95M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 7.63M - 8.26M 8.15M 6.49M
Additional paid in capital - - - - -
Common stock total equity - - - 0.00300M 143.06M
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 1.36M -31.57370M 0.76M 0.00100M 0.00000M
Deferred long term asset charges - - - - -
Non current assets total 10.81M 31.57M 4.17M 4.08M 1.51M
Capital lease obligations 0.92M - 0.88M 1.92M 0.05M
Long term debt total - 0.00000M 0.00000M 0.00000M 0.05M
Breakdown 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Type yearly yearly yearly yearly yearly
Date 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Investments -19.33200M -99.10000M -1.17400M -0.84700M -1.79461M
Change to liabilities 0.03M -1.03000M -0.69300M 2.44M 2.24M
Total cashflows from investing activities -19.33200M -99.36400M -1.17400M -0.84700M -1.22700M
Net borrowings - -0.00200M -0.01100M -0.04200M -0.06200M
Total cash from financing activities 0.90M 88.17M 64.05M 77.06M 28.92M
Change to operating activities -0.45800M 10.74M -4.51900M 0.09M 2.31M
Net income -26.66500M -34.60293M -26.58300M -42.03000M -24.62408M
Change in cash -37.54800M 40.96M 37.11M 53.47M 9.92M
Begin period cash flow 55.71M 106.99M 73.84M 20.37M 10.38M
End period cash flow 18.16M 147.96M 110.95M 73.84M 20.30M
Total cash from operating activities -19.09000M -24.82432M -25.90100M -22.74700M -19.24928M
Issuance of capital stock 0.00000M - 69.11M 81.70M 31.54M
Depreciation 0.57M 0.93M 0.71M 0.47M 0.26M
Other cashflows from investing activities -18.88000M -49.55000M - - -
Dividends paid - - - - -
Change to inventory -0.37100M -0.19819M -0.74500M -0.46800M 0.07M
Change to account receivables -0.39500M -1.64193M -1.39900M -0.72900M -0.72900M
Sale purchase of stock 0.90M 0.00700M 69.17M 82.18M 45.49M
Other cashflows from financing activities 0.90M 88.17M -5.04600M -4.60300M -2.57706M
Change to netincome 7.87M 7.51M 6.85M 17.49M 2.31M
Capital expenditures 0.53M 0.67M 1.17M 0.85M 1.26M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital -1.19600M -1.84011M -7.35600M 1.33M 3.35M
Stock based compensation 7.00M 8.71M 5.66M 16.59M 1.95M
Other non cash items 1.21M 1.98M 1.66M 0.90M 0.06M
Free cash flow -19.61500M -25.49458M -27.07500M -23.59400M -20.50611M

Fundamentals

  • Previous Close 2.55
  • Market Cap349.59M
  • Volume441200
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-41.93600M
  • Revenue TTM50.14M
  • Revenue Per Share TTM1.98
  • Gross Profit TTM 28.38M
  • Diluted EPS TTM-0.42

Peer Comparison

Sector: Healthcare Industry: Medical Devices

Company Change (AUD) Price (AUD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
AVH
Avita Therapeutics Inc		 0.23 9.02% 2.78 - - 8.59 5.71 6.72 -10.0538
COH
Cochlear Ltd		 0.73 0.22% 325.65 60.71 46.30 9.75 11.76 9.62 36.63
PNV
Polynovo Ltd		 0.01 0.45% 2.24 - 140.85 17.37 21.49 17.51 647.42
AVR
Anteris Technologies Ltd		 -0.55 2.61% 20.50 - - 104.23 14.98 95.15 -5.9152
EBR
Ebr Systems Inc CDR		 0.01 1.01% 1.00 - - - 5.68 - -7.482

Reports Covered

Stock Research & News

View All

Profile

AVITA Medical, Inc., together with its subsidiaries, operates as a regenerative medicine company in the United States and internationally. The company's lead product is the RECELL System, a cell harvesting device used for the treatment of thermal burn wounds, full-thickness skin defects, and repigmentation of stable depigmented vitiligo lesions. It develops RECELL GO to control the manual process of disaggregation, filtration, and soak time. The company was formerly known as AVITA Therapeutics, Inc. AVITA Medical, Inc. was incorporated in 2020 and is headquartered in Valencia, California.

Avita Therapeutics Inc

28159 Avenue Stanford, Valencia, CA, United States, 91355

Key Executives

Name Title Year Born
Mr. James M. Corbett CEO, Pres & Exec. Director 1958
Mr. Michael Bria Holder MBA Chief Financial Officer 1963
Ms. Kathy M. McGee Chief Operating Officer 1966
Mr. Andrew Quick Chief Technology Officer 1971
Ms. Donna Shiroma Gen. Counsel & Sec. 1962
Ms. Erin Liberto Chief Commercial Officer 1975
Mr. David Fencil VP of Global Operations NA
Ms. Debbie Garner VP of Global Marketing NA
Mr. James M. Corbett CEO, President & Executive Director 1958
Ms. Donna Shiroma General Counsel & Secretary 1962

Disclaimer - Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peer trades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).

Our Company

Useful Links

Contact Us

Market Research

Our Company

Useful Links

Contact Us

Disclaimer

The information given by Kalkine Pty Ltd ABN34 154 808 312 (Australian Financial Services License Number 425376) on this website is general information or advice only.

It does not take into account any of your personal objectives, circumstances or needs. Choosing an investment is an important decision. If you do not feel confident making a decision based on the recommendations Kalkine has made in our reports, you should consider obtaining personal advice from an authorised adviser.

There may be a product disclosure statement or other offer document for the securities and financial products we write about in Kalkine Reports. You should obtain a copy of the product disclosure statement or offer document before making any decision about whether to acquire the security or product. Terms & Conditions have been provided for our services, please go through them and also read our Financial Services Guide.

Our website may contain information on past performance of particular investments. Past performance is not an indicator of future performance. Hypothetical returns may not reflect actual performance. Any displays of potential investment opportunities are for sample purposes only and may not actually be available to investors.

The information on the website does not constitute an offer to sell securities or a solicitation of an offer to buy securities. Our reports contain general recommendations to invest in securities.

Copyright 2024 Krish Capital Pty. Ltd. All rights reserved. No part of this website, or its content, may be reproduced in any form without our prior consent.